Scholar IQ
Try ScholarIQ free
Upload Records Snowball Search Search OpenAlex
About the database
On this page:OverviewPublicationsKey papers
ScholarIQanswers from OpenAlex & ORCID

David A. Roth

ResearcherPublications, citations & collaboration network

David A. Roth is a researcher indexed in ScholarIQ from OpenAlex & ORCID. ScholarIQ records 284 works, 26,899 citations, an h-index of 55 and an i10-index of 132.

284
Works
26,899
Citations
55
h-index
132
i10-index

How has David A. Roth's publication output changed over time?

ScholarIQpublication output · 1990–2021

Output grew0% over the shown period — from 1 works in 1990 to 1 in 2021.

1
1
1
2
1
1
1
1
2
1
1990199920002001200420122017201820202021

What are the most-cited papers on David A. Roth?

ScholarIQmost cited works
A More Accurate Method To Estimate Glomerular Filtration Rate from Serum Creatinine: A New Prediction Equation
Andrew S. Levey, Juan Bosch, Julia B. Lewis, Tom Greene, Nancy Rogers, David A. Roth, for the Modification of Diet in Renal Disease Study Group*
Annals of Internal Medicine. 199915,156 Citations
Two-Year, Randomized, Controlled Trial of Belimumab in Lupus Nephritis
Richard Furie, Brad H. Rovin, Frédéric Houssiau, Ana Malvar, Y K Onno Teng, Gabriel Contreras, Zahir Amoura, Xueqing Yu, Chi-Chiu Mok, Mittermayer B. Santiago, Amit Saxena, Yulia Green, Beulah Ji, C. Kleoudis, Susan W. Burriss, Carly Barnett, David A. Roth
New England Journal of Medicine. 20201,005 CitationsOPEN ACCESS
Sequential Therapies for Proliferative Lupus Nephritis
Gabriel Contreras, Victoriano Pardo, Baudouin Leclercq, Oliver Lenz, Elaine Tozman, Patricia O'Nan, David A. Roth
New England Journal of Medicine. 2004820 Citations
The evaluation of renal transplantation candidates: clinical practice guidelines.
Bertram L. Kasiske, Charles B. Cangro, Sundaram Hariharan, Dondald E Hricik, Ronald H. Kerman, David A. Roth, David N. Rush, Miguel A. Vazquez, Matthew R. Weir
PubMed. 2001726 Citations
Efficacy and Safety of Subcutaneous Belimumab in Systemic Lupus Erythematosus: A Fifty‐Two–Week Randomized, Double‐Blind, Placebo‐Controlled Study
William Stohl, Andreas Schwarting, Masato Okada, Morton Scheinberg, Andrea Doria, Anne E. Hammer, C. Kleoudis, James Groark, Damon Bass, Norma Lynn Fox, David A. Roth, David Gordon
Arthritis & Rheumatology. 2017422 CitationsOPEN ACCESS

Related on ScholarIQ

GlaxoSmithKline (United States)
Institution
A More Accurate Method To Estimate Glomerular Filtration Rate from Serum Creatinine: A New Prediction Equation
Paper
Two-Year, Randomized, Controlled Trial of Belimumab in Lupus Nephritis
Paper
Sequential Therapies for Proliferative Lupus Nephritis
Paper
The evaluation of renal transplantation candidates: clinical practice guidelines.
Paper
Efficacy and Safety of Subcutaneous Belimumab in Systemic Lupus Erythematosus: A Fifty‐Two–Week Randomized, Double‐Blind, Placebo‐Controlled Study
Paper
470M+ articles · free account